|
|||||||||||||
|
|||||||||||||
Case Report | |||||||||||||
|
|||||||||||||
Volume 2, Number 5, October 2011, pages 206-209 | |||||||||||||
|
|||||||||||||
Significant Restenosis of Multiple Saphenous Vein Grafts Early After Coronary Artery Bypass Graft Surgery:
a Case Report
Davran
Ciceka,
c,
Seher
Gokaya,
Haldun Muderrisoglub
aDepartment
of Cardiology, Başkent University School of Medicine, Antalya,
Turkey
Manuscript
accepted for publication June 30, 2011
Abstract
Despite the
benefits of Coronary Artery Bypass Graft surgery, 15% to 25% of
patients develop graft closure within one year following the
procedure. The patency rate of grafts mainly predicts both the
short- and long-term benefit from surgery. Here we report a patient
diagnosed as acute coronary syndrome five months after surgery with
significant stenosis of multiple saphenous vein grafts. Keywords: Coronary Artery Bypass Graft Surgery; Saphenous Vein Grafts; Restenosis
Introduction
Coronary
angioplasty has become a mainstay in the treatment of ischemic heart
disease in the last decade, but it is not a relevant modality in
patients with significant (≥
50%) left main coronary artery disease (LMCD). On the other hand,
Coronary Artery Bypass Graft (CABG) surgery has been demonstrated in
both observational and randomized trials to prolong survival in
those patients [1].
Despite the benefits of CABG surgery, 15% to 25% of patients develop
graft closure within one year following the procedure [2].
Furthermore, the patency rate of grafts mainly predicts both the
short- and long-term benefit from CABG surgery [3].
Ischemia after CABG may be due to new disease, progression beyond
the bypass graft anastomosis, or disease in the graft itself [4].
Teixeira et al. reported that a history of CABG was an independent
predictor for a future readmission for unstable angina, and they
found the time between CABG surgery and the acute coronary syndrome
(ACS) to vary between a median of 4 to 12.5 years [5].
The present paper reports an ACS patient five months after CABG
surgery.
Case Report
An increasing number of patients who have had CABG and later have recurrent ischemia undergo revascularization with a percutaneous interventional technique [6]. Although data on percutaneous revascularization of saphenous venous grafts are still debated, studies showed no statistical difference in restenosis during a 6-month period, but with an improved clinical outcome for elective stenting [5]. Because of the initial higher mortality of redo CABG and the comparable long-term mortality, PCI is the preferred revascularization strategy in patients with patent left internal torasic artery (ITA) and amenable anatomy [4]. In the AWESOME RCT and registry, overall in-hospital mortality was higher with CABG than with PCI [7]. A new major coronary event after CABG surgery can be due to progression of atherosclerosis in native arteries and/or development of vascular disease in the graft [5]. Both events were true for this patient, especially with regard to ostial lesions. Experimental studies and observations in patients suggest that the development of disease in venous aortocoronary artery bypass grafts occurs in several phases. Early occlusion (before hospital discharge) occurs in 8 to 12 percent of venous grafts, and by year, 15 to 30 percent of vein grafts have become occluded [8] Vein grafts that have been implanted in the arteriel circulation for 1 month to 1 year are subject to substantial endothelial denudation and proliferation and to migration of medial cells to the intima. Migration of vascular smooth muscle cells through the internal elastic lamina into the intima may also occur [9]. If the proliferation is severe and localized as may occur at the side of anastomosis between grafts and the recipient artery total occlusion can occur within one year, which is intermediate phase occlusion, as it probably happened in our case we presented. Can LH et al. conducted a study [10] with ACS patients following CABG surgery, and stated that the main reason for ACS was the insufficient patient compliance with regard to the use of statins and ACE inhibitors, with only about 25% of the patients sticking to their prescribed therapy. Our patient claimed to have been using all of his coronary artery disease medications. His low density lipoprotein (LDL) level, however, was 111 mg/dL (above 100 mg/dL). His statin dose was 20 mg, and needed to be increased. Based on previous studies, the role of LDL-cholesterol in disease progression in native vessels as well as in by-pass grafts, has been well known [11]. A previous study reported on GGT levels was independently associated with SVG disease. In our case GGT level was normal which was inconsistent with the study [3]. Patients with a history of CABG are reported to be admitted more often for a non-ST-elevation ACS and also to have lower peak values of cardiac biomarkers for necrosis [12]. Our case’s cardiac markers were similarly low, the troponin level being 0.362 ng/mL (normal < 0.020 ng/mL. According to Crean et al. [12]. this may probably be related to the dual circulation and the more common occlusion of secondary branches is due to the protection of the main coronary arteries by the bypass vessels. The case presented here might be of interest for the significantly shorter time interval between the ACS and the prior CABG surgery than the interval varying between the median of 4-12.5 years, as reported in the previous study [5]. Conclusion
Secondary
prevention is as important as primary prevention in coronary artery
disease patients. Furthermore, cardiologists should keep in mind
that despite all types of preventions acute coronary syndrome can
occur within less than one year after CABG. Conflict of Interest
The authors
declare that they have no competing interests. Consent
Written informed
consent was obtained from the patient for publication of this case
report and accompanying images. A copy of the written consent is
available for review by the Editor-in-Chief of this journal. Authors’ contributions
SB and DC performed the coronary angiography and were
major contributors in writing the manuscript. SB, DC and HM worked
together in writing the manuscript. All authors read and approved
the final manuscript. |
|||||||||||||
|
|||||||||||||
References | |||||||||||||
1. |
Caracciolo EA, Davis KB, Sopko G, Kaiser GC, Corley SD,
Schaff H, Taylor HA, et al. Comparison of surgical and medical group
survival in patients with left main coronary artery disease. Long-term
CASS experience. Circulation. 1995;91(9):2325-2334. [Medline] |
2. |
Okrainec K, Pilote L, Platt R, Eisenberg MJ. Use of cardiovascular
medical therapy among patients undergoing coronary artery bypass graft
surgery: results from the ROSETTA-CABG registry.
Can J Cardiol. 2006;22(10):841-847. [Medline] |
3. |
Demirkan B, Guray Y, Guray U, Turak O, Hajro E, Korkmaz S. The
relationship between saphenous coronary bypass graft occlusion and serum
gamma-glutamyltransferase activity.
Turk Kardiyol Dern
Ars.
2010;38(5):321-326. [Medline] |
4. |
Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, Garg S, et
al. Guidelines on myocardial revascularization: The Task Force on
Myocardial Revascularization of the European Society of Cardiology (ESC)
and the European Association for Cardio-Thoracic Surgery (EACTS).
Eur Heart J. 2010;31(20):2501-2555. [Medline] |
5. |
Teixeira R, Lourenco C, Antonio N, Jorge E, Baptista R, Saraiva F,
Mendes P, et al. Can we improve outcomes in patients with previous
coronary artery bypass surgery admitted for acute coronary syndrome?
Rev Esp Cardiol. 2010;63(5):554-563.
[Medline] |
6. |
Mathew V, Clavell AL, Lennon RJ, Grill DE, Holmes DR, Jr.
Percutaneous coronary interventions in patients with prior coronary
artery bypass surgery: changes in patient characteristics and outcome
during two decades.
Am J Med.
2000;108(2):127-135. [Medline] |
7. |
Morrison DA, Sethi G, Sacks J, Henderson W, Grover F, Sedlis S, Esposito
R, et al. Percutaneous coronary intervention versus coronary artery
bypass graft surgery for patients with medically refractory myocardial
ischemia and risk factors for adverse outcomes with bypass: a
multicenter, randomized trial. Investigators of the Department of
Veterans Affairs Cooperative Study #385, the Angina With Extremely
Serious Operative Mortality Evaluation (AWESOME).
J Am Coll Cardiol. 2001;38(1):143-149. [Medline] |
8. |
Bourassa MG. Long-term vein graft patency.
Curr Opin Cardiol. 1994;9(6):685-691. [Medline] |
9. |
Bryan AJ, Angelini GD. The biology of saphenous vein graft occlusion:
etiology and strategies for prevention.
Curr Opin Cardiol. 1994;9(6):641-649. [Medline] |
10. |
Can LH, Kayikcioglu M, Yavuzgil O, Kultursay H, Soydan I.
Evaluation of hospitalization period and five-year follow-up of patients
admitted with acute coronary syndrome following coronary artery bypass
graft surgery.
Turk Kardiyol Dern
Ars. 2010;38(6):387-392. [Medline] |
11. |
Campeau L, Enjalbert M, Lesperance J, Bourassa MG, Kwiterovich P, Jr.,
Wacholder S, Sniderman A. The relation of risk factors to the
development of atherosclerosis in saphenous-vein bypass grafts and the
progression of disease in the native circulation. A study 10 years after
aortocoronary bypass surgery.
N Engl J Med. 1984;311(21):1329-1332. [Medline] |
12. |
Crean PA, Waters DD, Bosch X, Pelletier GB, Roy D,
Theroux P. Angiographic findings after myocardial infarction in patients
with previous bypass surgery: explanations for smaller infarcts in this
group compared with control patients. Circulation. 1985;71(4):693-698.
[Medline] |
Digital Object Identifier (DOI):10.4021/jmc248e
About
DOI and
CrossRef
Journal of Medical Cases is a member of CrossRef.